Wedbush Thinks Lexicon Pharmaceuticals’ Stock is Going to Recover

By Ryan Adsit

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (LXRXResearch Report) today and set a price target of $35. The company’s shares opened today at $5.38, close to its 52-week low of $4.25.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -8.1% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lexicon Pharmaceuticals with a $20 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.97 and a one-year low of $4.25. Currently, Lexicon Pharmaceuticals has an average volume of 778.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.